Evidence map›Paper›PMID 33928024›Full record

ArticleFrontiers in oncology2021

Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses.

Wei Zhang, Qi Yin, Haidong Huang, Jingjing Lu, Hao Qin, Si Chen, Wenjun Zhang, Xiaoping Su, Weihong Sun, Yuchao Dong and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 20 citations in OpenAlex.

  1. Human Organoids as a Novel Tool for Vaccine Study.Advanced healthcare materials · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Clinical Value of Cytokine Assay in Diagnosis and Severity Assessment of Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  14. Review
  15. Review
  16. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.International journal of biological sciences · 2022
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Wei ZhangDepartment of Pulmonary and Critical Care Medicine, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Qi YinDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.
Haidong HuangDepartment of Pulmonary and Critical Care Medicine, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Jingjing LuDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.
Hao QinDepartment of Pulmonary and Critical Care Medicine, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Si ChenDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.
Wenjun ZhangDepartment of Emergency, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Xiaoping SuSchool of Basic Medicine, Wenzhou Medical University, Wenzhou Tea Mountain Higher Education Park, Wenzhou, China.
Weihong SunBiotherapy Center, Qingdao Central Hospital, The Second Affiliated Hospital, Qingdao University, Qingdao, China.
Yuchao DongDepartment of Pulmonary and Critical Care Medicine, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Qiang LiDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.
Second Military Medical University · CNShanghai East Hospital · CNChanghai Hospital · CNQingdao University · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop a neoantigen-targeted personalized cancer treatment for non-small cell lung cancer (NSCLC), neoantigens were obtained from collected human lung cancer samples, and the utility of neoantigen and neoantigen-reactive T cells (NRTs) was assessed.

methodsTumor specimens from three patients with NSCLC were obtained and analyzed by whole-exome sequencing, and neoantigens were predicted accordingly. Dendritic cells and T lymphocytes were isolated, NRTs were elicited and IFN-γ ELISPOT tests were conducted. HLA-A2.1/K

resultsMultiple putative mutation-associated neoantigens with strong affinity for HLA were selected from each patient. Immunogenic neoantigen were identified in all three NSCLC patients, the potency of ACAD8-T105I, BCAR1-G23V and PLCG1-M425L as effective neoantigen to active T cells in suppressing tumor growth was further proven both

conclusionNeoantigens with strong immunogenicity can be screened from NSCLC patients through the whole-exome sequencing of patient specimens and machine-learning-based neoantigen predictions. NRTs shown efficient antitumor responses in transgenic mice and tumor-bearing mouse models. Our results indicate that the development of neoantigen-based personalized immunotherapies in NSCLC is possible. PRECIS: Neoantigens with strong immunogenicity were screened from NSCLC patients. This research provides evidence suggesting that neoantigen-based therapy might serve as feasible treatment for NSCLC.

Indexed as

immunotherapyneoantigenneoantigen-reactive T cells (NRTs)non-small cell lung cancer (NSCLC)tumor vaccine

Identifiers

PMID33928024
PMCPMC8076796
OpenAlexW3154652405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.